We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Using our unique chemistry and biological expertise, we have developed an integrated approach to identify and overcome the limitations of current cancer therapeutics, enabling us to design better small molecules for improved patient outcomes.
CompoundComp | IndicationInd | Development ApproachDev | PreclinicalPre | Early Clinical DevelopmentEarly | Late Clinical DevelopmentLate | |||
|---|---|---|---|---|---|---|---|---|
|
Azenosertib
(ZN-c3) Wee1 Inhibitor |
Uterine Serous Carcinoma |
Monotherapy |
Uterine Serous Carcinoma
Monotherapy
|
|||||
Solid Tumors |
Monotherapy |
Solid Tumors
Monotherapy
|
||||||
Cyclin E Driven High Grade Serous Ovarian |
Monotherapy |
Cyclin E Driven High Grade Serous Ovarian
Monotherapy
|
||||||
PARP Resistant Ovarian Cancer |
Monotherapy alternating with niraparib or concurrent with niraparib |
PARP Resistant Ovarian Cancer
Monotherapy alternating with niraparib or concurrent with niraparib
|
||||||
Ovarian Cancer |
+ Multiple Chemotherapy Backbones |
Ovarian Cancer
+ Multiple Chemotherapy Backbones
|
||||||
Osteosarcoma |
+ gemcitabine |
Osteosarcoma
+ gemcitabine
|
||||||
BRAF Mutant mCRC |
+ encorafenib and cetuximab |
BRAF Mutant mCRC
+ encorafenib and cetuximab
|
||||||
Pancreatic Cancer |
+ gemcitabine |
Pancreatic Cancer
+ gemcitabine
|
||||||
|
ZN-d5
BCL-2 Inhibitor |
AL Amyloidosis |
Monotherapy |
AL Amyloidosis
Monotherapy
|
|||||
NHL |
Monotherapy |
NHL
Monotherapy
|
||||||
AML |
+ azenosertib |
AML
+ azenosertib
|
||||||
|
BCL-xL
Degrader |
Solid Tumors and Heme Malignancies |
Solid Tumors and Heme Malignancies
|
||||||